Ozempic in New Zealand: What You Need to Know Before You Start

Ozempic and Wegovy contain semaglutide, but their NZ indications and supply position differ. Wegovy is the brand approved for weight management. Start by confirming which product your prescriber means. 1 2

NZ availability and Medsafe status

As checked on 6 September 2026, Medsafe records Ozempic approval, including a presentation approved on 16 March 2023. That record currently says Not available. Approval is not confirmation of pharmacy supply. 1

Ozempic's listed uses concern type 2 diabetes, including kidney and cardiovascular risk reduction in adults with diabetes and chronic kidney disease. Weight management alone is not a listed indication. 1

Using Ozempic specifically for weight management would therefore be off-label. Ask your prescriber to explain the product, indication and supply arrangements rather than assuming all semaglutide prescriptions are equivalent. 1

Wegovy received Medsafe consent on 20 March 2025. Its adult weight-management indication accompanies dietary changes and physical activity, with these initial BMI criteria: 2

• BMI of 30 or above.
• BMI from 27 to below 30 with at least one weight-related condition.

Its cardiovascular indication covers adults with established cardiovascular disease, BMI of at least 27, and no established type 1 or type 2 diabetes. Separate adolescent criteria also apply. 2

Mounjaro contains tirzepatide, not semaglutide. It received consent on 22 December 2025 for adult type 2 diabetes and chronic weight management. These are prescription medicines, not interchangeable brand names. 3

Pharmac funding

Pharmac's published position identifies Wegovy and Mounjaro as unfunded. Wegovy is on its Options for Investment List, but consideration does not establish whether or when funding will begin. 4

Dulaglutide and liraglutide have funding for eligible people with type 2 diabetes. Access widened on 1 September 2026, but this did not create weight-loss funding. 5

The criteria include HbA1c remaining above 53 mmol/mol despite at least six months of empagliflozin, metformin and vildagliptin, where clinically appropriate. This is a funding rule, not everyone's treatment target. 5

Funded concurrent empagliflozin and GLP-1 treatment is restricted, with an exception for empagliflozin used for heart failure. Your prescriber should assess the complete criteria, not HbA1c alone. 5

Access and cost

On 6 September 2026, Chemist Warehouse NZ advertised these Wegovy prices. They are a retailer snapshot, not Ozempic prices or a national tariff. 6

Each pen contains four weekly doses, so compare four-week costs rather than assuming a calendar month. 2

Buying one pen at each listed strength totals NZ$2,074.95. This five-pen example could cover 20 weekly doses, not exactly 18 weeks. It is budgeting arithmetic, not a recommended dose progression. 2 6

Ask for a quote covering your prescribed strengths, consultations, dispensing and supplies. Request a separate quote for Mounjaro rather than applying Wegovy prices to it.

For broader comparisons, see GLP-1 access in New Zealand.

Side effects and questions before starting

Nausea, vomiting, diarrhoea and constipation can occur with Wegovy. Persistent symptoms deserve review, especially if you cannot eat or drink adequately. Vomiting and diarrhoea can cause dehydration. 7

Before starting, discuss your medicines and medical history, particularly insulin or sulfonylureas, delayed stomach emptying, and diabetic eye disease. Your prescriber should manage any medication changes. 7

Discuss pregnancy plans early. Semaglutide should not be used during pregnancy; the product information specifies at least two months without treatment before a planned pregnancy. Arrange this with your prescriber. 7

Seek urgent medical attention for severe, persistent abdominal pain, especially with vomiting or pain reaching your back. Breathing difficulty or swelling of the face or throat needs emergency help. 7

Tell your healthcare team before any procedure involving general anaesthesia or deep sedation. Read the medicine's consumer information for the full precautions. 7

Common nutrition mistakes on semaglutide

Reduced appetite makes food quality important. Practical priorities include: 8

• Include protein foods such as eggs, yoghurt, fish or beans. Individualise the target rather than automatically increasing intake.
• Keep vegetables, fruit, whole grains and other nutrient-rich foods in the plan. Smaller meals may be easier when appetite is low.
• Combine adequate protein with strength training suited to your ability. Protein alone is not a substitute for training.
• Review a persistently restricted intake. Supplements or blood tests should address identified risks, not an assumed deficiency in every user. 8

See GLP-1 nutrition and muscle preservation for more detail.

What nutrition coaching and monitoring can do

Support can help organise meals, review intake and plan activity before treatment or once it is underway. The professional advisory supports these priorities, but does not prove that commercial coaching guarantees better outcomes. 8

BIA estimates body composition using electrical measurements and body-water assumptions. Hydration can affect those estimates, so a change in estimated fat-free mass is not proof of equivalent skeletal muscle loss. 9

Track strength and everyday function alongside weight trends. Scans are optional supporting information, not a requirement for getting value from treatment. 8

For measurement context, see BIA versus DEXA. For help organising everyday eating, you can ask about nutrition coaching.

How long treatment lasts and what happens after stopping

Do not assume semaglutide is a short course. Wegovy's indication includes weight maintenance, and duration should be reviewed with your prescriber against benefits, side effects and affordability. 2

In the STEP 1 extension, participants previously taking semaglutide 2.4 mg regained about two-thirds of their lost weight, on average, during the year after treatment stopped. Individual outcomes varied. 10

Both medication and structured lifestyle support stopped. This limits what the study can tell us about continued support, and it does not establish that better habits or coaching would prevent regain. 10

Regain is not proof of personal failure. Agree a follow-up plan before any change, including how weight, appetite and relevant health measures will be reviewed. Nutrition support complements that plan; it cannot promise lasting loss. 10